An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: Implications on the use of adjuvant therapy

Urology

Volumn 47, Issue 4, 1996, Pages 538-547

  D'Amico, Anthony V ^a   Whittington, Richard ^b   Malkowicz, S Bruce ^b   Loughlin, Kevin ^b   Schultz, Delray ^b   Schnall, Mitch ^b   Tempany, Clare M ^b   Tomaszewski, John E ^b   Renshaw, Andrew ^b   Wein, Alan ^b  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ARTICLE; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; SURVIVAL RATE;

EID: 0029948774     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80492-0     Document Type: Article

References (29)

1. Anscher MS, and Prosnitz LR: Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 138: 1407-1412, 1987.
2. Carter GE, Liekovsky G, Skinner DG, and Petrovich Z: Results of local and/or systemic adjuvant therapy in the management of pathological stage C or D1 prostate cancer following radical prostatectomy. J Urol 142: 1266-1271, 1989.
3. Forman JD, Wharan MD, Lee DJ, Zinreich ES, and Order SE: Definitive radiotherapy following prostatectomy: results and complications. Int J Radiat Oncol Biol Phys 12: 185-189, 1986.
4. Freeman JA, Lieskovsky G, Cook DW, Petrovich Z, Chen S, Groshen S, and Skinner DG: Radical retropubic prostatectomy and postoperative adjuvant radiation for pathological stage C (PCNO) prostate cancer from 1976 to 1989: intermediate findings. J Urol 149: 1029-1034, 1993.
5. Gibbons RP, Cole BS, Richardson RG, Correa RJ Jr, Brannen GE, Mason JT, Taylor WJ, and Hafermann MD: Adjuvant radiotherapy following radical prostatectomy: results and complications. J Urol 135: 65-68, 1986.
6. Jacobson GM, Smith JA Jr, and Stewart JR: Postoperative radiation therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 13: 1021-1024, 1987.
7. Meier R, Mark R, St Royal L, Tran L, Colburn G, and Parker R: Postoperative radiation therapy after prostatectomy for prostate carcinoma. Cancer 70: 1960-1966, 1992.
8. Petrovich Z, Lieskovsky G, Langholz B, Luxton G, Jozsef G, and Skinner DG: Radiotherapy following radical prostatectomy in patients with adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 21: 949-954, 1991.
9. Pilepich MV, Walz BJ, and Baglan RJ: Postoperative irradiation in carcinoma of the prostate. Int J Radiat Oncol Biol Phys 10: 1869-1873, 1984.
10. Shevlin BE, Mittal BB, Briand WN, and Shetty RM: The role of adjuvant irradiation following primary prostatectomy, based on histopathologic extent of tumor. Int J Radiat Oncol Biol Phys 16: 1425-1430, 1989.
11. Hanks GE, and Dawson AK: The role of external beam radiation after prostatectomy for prostate cancer. Cancer 58: 2406-2410, 1986.
12. Epstein JI, Pizov G, and Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582-3593, 1993.
13. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43: 649-659, 1994.
14. Myrtle JF, Klimley PG, Ivor LP, and Brun JF: Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer, in: Advances in Cancer Diagnosis, Hybritech, 1986.
15. Beahrs OH, Henson DE, Hutter RV, and Kennedy BJ: American Joint Committee on Cancer, Manual for Staging, 4th ed. Philadelphia, JB Lippincott, 1992.
16. Schnall MD, Lenkinski RE, Pollack HM, Imai Y, and Kressel HY: Prostate: MR imaging with an endorectal surface coil. Radiology 172: 570-574, 1989.
17. Schiebler ML, Schnall MD, Pollack HM, Lenkinski RE, Tomaszewski JE, Wein AJ, Whittington R, Rauschning W, and Kressel HY: Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology 189: 339-352, 1993.
18. Cox DR: Regression models and life tables. J R Stat Soc B34: 1,1972.
19. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, and Wein A: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 154: 131-138, 1995.
20. Kabalin JN, McNeal JE, Johnstone IM, and Stamey TA: Serum prostate-specific antigen and the biologic progression of prostate cancer. Urology 46: 65-70, 1995.
21. Zagars GK, Ayala AG, von Eschenbach AC, and Pollack A: The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 31: 237-245, 1995.
22. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, and Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850-1857, 1994.
23. Cox RS, Kaplan ID, and Bagshaw MA: Prostate-specific antigen kinetics after external beam irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 28: 23-31, 1994.
24. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, and Warner J: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330: 242-248, 1994.
25. Levesque PE, Nieh PT, Zinman L, Malone MJ, Seldin D, Libertino JA: Monoclonal antibody scans detect sites of prostate cancer beyond standard node dissections (abstract 11). Proceedings of the 64th Annual Meeting of the New England American Urological Association, 1995, p 82.
26. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
27. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, and Stamey TA: Patterns of progression in prostate cancer. Lancet 1: 60-63, 1986.
28. McNeal JE: Cancer volume and site of origin of adenocarcinoma of the prostate: relationship to local and distant spread. Hum Pathol 23: 258-266, 1992.
29. Catalona WJ, and Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152: 1837-1842, 1994.